Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer

• Published in: Frontiers in oncology Vol. 15; p. 1614434
• Main Authors: Zhou, Fang, Liu, Shushu, Zuo, Ying, Naseem, Danial F., Li, Yinguang, Wang, Yin, Meng, Cuicui, Song, Yipeng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.06.2025
• Subjects: anti-angiogenesis therapy; cervical cancer; CTLA-4; immunotherapy; Oncology; PD-1; anti-angiogenesis therapy; CTLA-4; PD-1; cervical cancer; immunotherapy
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2025.1614434

Combined immunotherapy and antiangiogenic therapy have exhibited synergistic antitumor effects in several cancers. The prognosis of recurrent or metastatic cervical cancer (r/mCC) is poor, especially for patients with prior multi-line treatments. This study aimed to evaluate the efficacy and safety of cadonilimab(PD-1/CTLA-4 bispecific)with anti-angiogenesis adjuvant therapy (bevacizumab or anlotinib) in pretreated patients with r/mCC. Nineteen patients treated with cadonilimab plus bevacizumab or anlotinib with or without chemotherapy were included. Cadonilimab was administered at dose of 10mg/kg intravenously. Patients receiving anti-angiogenic therapy received either bevacizumab or anlotinib administered orally. The safety, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were assessed. The median follow-up was 15.5 months study patients. Among all 19 patients, 2 patients (10.5%) achieved complete response (CR), 2 patients (10.5%) achieved partial response (PR) and 4 patients (21.1%) achieved stable disease (SD), with an ORR of 21.1% and DCR of 42.1%. Moreover, the median PFS was 10.5 months (95% CI: 6.1-14.9 months) and 1-year OS rate was 78.3%. Proteinuria (47.4%) and hypertension (42.2%) were the most common treatment-related adverse events (TRAE), with 5 (26.3%) patients experiencing Grade 3 TRAEs, while no treatment related deaths were observed. This is the first report exploring the efficacy and safety of treating patients concurrently with Cadonilimab plus bevacizumab or anlotinib with heavily pretreated r/mCC. The findings suggest that this regimen might be potentially efficacious and safe with relatively manageable toxicity. Further trials with a control arm are required to validate our findings.